Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

S. Bresalier, Robert; S. Sandler, Robert; Quan, Hui; A. Bolognese, James; Oxenius, Bettina; Horgan, Kevin; Lines, Christopher; H. Riddell, Robert; Morton, Dion; Lanas, Ángel; A. Konstam, Marvin; A. Baron, John

doi:10.1056/nejmoa050493

Public

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

Published in New England Journal of Medicine • Feb 16, 2005

Authors:

Robert S. Bresalier

Robert S. Sandler

Hui Quan

Abstract

BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in...

Subject

Medicine

Rofecoxib

Colorectal adenoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!